Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Genmab, de Deense parel

3.460 Posts
Pagina: «« 1 ... 168 169 170 171 172 173 | Laatste | Omlaag ↓
  1. sheriff Grover 23 januari 2024 00:44
    Arbitrage verloren ... hadden het in eerste abitrage moeten meenemen .. welnu : iig duidelijkheid !

    Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
    Company Announcement
    COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the appeal arbitrator in its second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab has denied Genmab’s appeal. As a result, the dismissal of Genmab’s claims in the second arbitration is now concluded. Genmab had appealed the tribunal’s two-to-one decision dismissing Genmab’s claims on the basis that the claims should have been brought in the prior arbitration between Genmab and Janssen.
    Genmab’s claims were based upon its position that the subcutaneous formulation of daratumumab (SC daratumumab, marketed as DARZALEX FASPRO® in the United States) is a new licensed product under the license agreement. The claims included both a claim for milestone payments with respect to SC daratumumab and a claim for a new 13-year royalty term, on a country-by-country basis, from the date of the first commercial sale of SC daratumumab in each such country. The decision in the arbitration appeal will have no effect on Genmab’s upcoming financial guidance for 2024.
    About Genmab
    Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO™) antibody medicines.
    Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
    Contact:
    Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
    T: +1 609 524 0065; E: mmp@genmab.com
    Andrew Carlsen, Vice President, Head of Investor Relations
    T: +45 3377 9558; E: acn@genmab.com
    This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

    Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO™. DARZALEX FASPRO® is a trademark of Johnson & Johnson.
    Company Announcement no. 02
    CVR no. 2102 3884
    LEI Code 529900MTJPDPE4MHJ122
    Genmab A/S
    Carl Jacobsens Vej 30
    2500 Valby
    Denmark
    Attachment
    • 230124_CA02_Claims Dismissed

    View this release ?

    Or click here to view all releases.
  2. Biotech1982 24 januari 2024 15:26
    Nou die kogel is door de kerk. En het was de laatste weken al aan de prijs te zien.. Insider information wellicht, we zullen er nooit achter komen.

    @Pokerface; Genman krijgt royalties over TEPEZZA (teprotumumab-trbw) (ik kan niet terugvinden hoeveel % van de netto opbrengsten, maar mid-single digit, ik vermoedt dan 5% oid. Dit kan behoorlijk oplopen.

    Voor TIVDAK (tisotumab vedotin-tftv) verwacht men in 2029 voor 750e6 USD aan sales, Genmab krijgt hier 50% van (50/50 met Seagen, ook de kosten).

    Epcoritamab (EPKINL) kan volgense GlobalData’s Pharma Intelligence Center 2.3e9 USD aan sales genereren in 2029. Genmab zal hier 22-26% van de net sales krijgen mits er geen fouten zijn gemaakt in de contracten ;)

    Verder kunnen er nog veel milestones gehaald worden waar ook weer geld van binnenkomt en natuurlijk lopen de inkomsten van Daratumumab eerst ook nog gewoon door ondanks het verlies van de rechtzaak.

    Veelal dus nog toekomstmuziek... Maar ik 1900DKK heb ik echt niet zien aankomen..
  3. Highlands 2 februari 2024 15:27

    Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
    Media Release

    COPENHAGEN, Denmark; February 2, 2024

    Validation is supported by data from Phase 3 innovaTV 301 trial

    Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab vedotin, an antibody-drug conjugate (ADC), developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. If approved, tisotumab vedotin would be the first ADC granted European Union (EU) marketing authorization for people living with cervical cancer.

  4. Biotech1982 29 februari 2024 09:02
    Je zou toch verwachten dat de aandeleninkoop door Genmab een positief effect zou hebben, dat valt ook tegen tot nu toe. Van 260DKK in 2000 (IPO) naar 1980 DKK in 2024, na 24 jaar, een rendement van bijna 9 procent per jaar compounded. Na 2015 had ik meer verwacht. We moeten maar weer afwachten.
  5. sheriff Grover 29 februari 2024 09:17
    Morguh Biotech 1982 , Sterker het is nog veel erger !

    Ik had het er toevallig van de week nog met een vriend (ook aandeelhouder) over wat iedereen vergeet is dat Genmab in 2000 rond de 30 miljoen uitstaande aandelen had , nu zitten we afgerond op 65 miljoen . Dus die 8 a 9 % mag je in principe nog eens door twee delen. En als je het zo bekijkt is het verre van een sprookje .... Wij kwamen tot de conclusie dat Shell over eenzelfde periode alleen met dividend en met heel veel minder hoofdpijn meer had opgebracht . Het geduld bij mij raakt aardig op moet ik bekennen .... we staan gewoon alweer 4 jaar stil koers technisch gezien.... gr SG
  6. Biotech1982 29 februari 2024 13:03
    Ai ja goed punt, ik heb de verwatering niet meegenomen. Ieder jaar wordt er zo'n 0.3% aan opties weggegeven aan het personeel, die dan als aandelen uitgeoefend kunnen worden geloof ik. En er is misschine na 2000 nog een 2de ronde aan aandele bijgekomen. Dan zou je op zo'n 5% compounded uitkomen inderdaad :(
3.460 Posts
Pagina: «« 1 ... 168 169 170 171 172 173 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 854,10 0,00%
EUR/USD 1,0848 +0,07%
FTSE 100 7.682,50 0,00%
Germany40^ 17.728,90 -0,03%
Gold spot 2.086,18 +0,16%
NY-Nasdaq Composite 16.274,94 +1,14%

Stijgers

AALBER...
0,00%
ABN AM...
0,00%
Accsys
0,00%
ACOMO
0,00%
ADYEN NV
0,00%

Dalers

AALBER...
0,00%
ABN AM...
0,00%
Accsys
0,00%
ACOMO
0,00%
ADYEN NV
0,00%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links